[Clinicopathological characteristics and prognosis of uterine malignant mixed Mullerian tumor].
To evaluate the clinicopathological characteristics, treatment and prognosis of uterine malignant mixed mullerian tumor.



The clinical, pathologic and follow-up data of 16 patients with uterine malignant mixed Mullerian tumor treated in our hospital between March, 2003 and June, 2015 were analyzed.



The 16 patients had a median age of 58 years at diagnosis, and 13 of them were postmenopausal. The number of patients with FIGO stage Ia, Ib, II, IIIa, IIIc2, and IV was 7, 3, 1, 3, 1, and 1, respectively. In 15 patients who received uterine segment diagnostic curettage, pathological examination all reported malignant results. Among the 15 patients having serum CA125 level test upon admission, 2 had elevated CA125 levels. The overall and disease-free survival rates of the 16 patients were 75% and 68.8%, respectively, and the 3-year survival rate of 13 patients who were followed up for at least 3 years was 72.7%. Two out of 12 patients receiving retroperitoneal lymph?node?dissection?had had postoperative recurrence, as compared with 3 out 4 who did not had the operation; tumor recurrence was found in 3 out of 13 patients receiving postoperative chemotherapy, as compared with 2 out of 3 patients who did not have chemotherapy; tumor recurrence occurred in 1 out of 10 patients receiving radiotherapy, as compared with 4 out of 6 patients without radiotherapy. The recurrence rates in 11 patients with FIGO stage I-II was 18.2%, and that among the 5 patients with FIGO stage III-IV was 60.0%.



Uterine segment diagnostic curettage has a high diagnostic value for uterine malignant mixed Mullerian tumor. FIGO stage is the important prognostic factor for these patients, and early?diagnosis, accurate surgical staging, platinum-based chemotherapy and postoperative pelvic radiotherapy are all associated with a better prognosis.
Department of Gynecologic Oncology, Cancer Hospital of Shantou University Medical College, Shantou 515041, China.E-mail: annazzhu@aliyun.com.
An-Na
AN
Zhu
Ming-Fei
MF
Guan
Yan
Y
Zhu
Yan
Y
Li
Li
L
Zhou
Cong-Zhu
CZ
Li
Ping
P
Huang
D018394:CA-125 Antigen / Q000097:blood; D005260:Female; D006801:Humans; D007044:Hysterectomy; D008565:Membrane Proteins / Q000097:blood; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D014594:Uterine Neoplasms / Q000175:diagnosis* / Q000473:pathology* / Q000628:therapy
D018394:CA-125 Antigen; C451759:MUC16 protein, human; D008565:Membrane Proteins